Abstract
Dengue viruses are the most common arthropod-transmitted viral infection, with an estimated 390 million human infections annually and ∼3.6 billion people at risk. Currently, there are no approved vaccines or therapeutics available to control the global dengue virus disease burden. In this study, we demonstrate the binding, neutralizing activity, and therapeutic capacity of a novel bispecific dual-affinity retargeting molecule (DART) that limits infection of all four serotypes of dengue virus.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Antibodies, Bispecific / genetics
-
Antibodies, Bispecific / immunology
-
Antibodies, Bispecific / therapeutic use*
-
Antibodies, Monoclonal / genetics
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Cross Reactions / immunology
-
Dengue / drug therapy*
-
Dengue / immunology
-
Dengue Virus / immunology*
-
Epitopes / genetics
-
Humans
-
Immunoglobulin Variable Region / genetics
-
Kaplan-Meier Estimate
-
Mice
-
Models, Molecular
-
Molecular Sequence Data
-
Molecular Targeted Therapy / methods*
-
Neutralization Tests
-
Species Specificity
-
Statistics, Nonparametric
-
Viral Vaccines / immunology
Substances
-
Antibodies, Bispecific
-
Antibodies, Monoclonal
-
Epitopes
-
Immunoglobulin Variable Region
-
Viral Vaccines